论文部分内容阅读
测定了原发性肝癌７７例（ＰＨＣ组），肝硬化３５例（ＤＣ组），消化系统其他恶性肿瘤患者３３例（ＤＳＣ组）及健康人１００例（ＮＣ组）血清α－Ｌ－岩藻糖苷酶（ＡＦＵ）活力。结果表明：ＰＨＣ组ＡＦＵ（６６９．６±１９１．５ｎｍｏｌ·ｍｌ￣（－１）·ｈ￣（－１））显著高于ＮＣ组（３１４．３±６７．０ｎｍｏｌ·ｍｌ￣（－１）·ｈ￣（－１），Ｐ＜０．０１），ＤＳＣ组（３９０．６±１０２．３ｎｍｏｌ·ｍｌ￣（－１）·ｈ￣（－１），Ｐ＜０．０１）和ＤＣ组（４５８．３±１５０．１ｎｍｏｌ·ｍｌ￣（－１）·ｈ￣（－１），Ｐ＜０．０５）。其诊断敏感性和特异性分别为７１．４％和８９．３％，与ＡＦＰ联合检测时ＰＨＣ组总的阳性检出率达８８．２％。
Seventy-seven cases of primary liver cancer (PHC group), 35 cases of liver cirrhosis (DC group), 33 cases of other malignant tumors of the digestive system (DSC group) and 100 cases of healthy people (NC group) were assayed. Glycosidase (AFU) activity. The results showed that: AFU (669.6±191.5 nmol·ml ̄(-1)·h ̄(-1)) in PHC group was significantly higher than that in NC group (314.3±67.0 nmol·ml ̄(-1)· h ̄(-1), P<0.01), DSC group (390.6±102.3 nmol·ml ̄(-1)·h ̄(-1), P<0.01) and DC group (458 .3±150.1 nmol·ml ̄(-1)·h ̄(-1), P<0.05). The diagnostic sensitivity and specificity were 71.4% and 89.3%, respectively, and the total positive detection rate of PHC group was 88.2% when combined with AFP.